Is there a role for statin therapy in heart failure? Join Drs John JV McMurray , Michel White, Jonathan Howlett, and Robert McKelvie as they discuss new data from the GISSI-HF and CORONA trials.
Navigating the SEAS: Join Drs Fitchett and Chan as they present their views on the latest controversial findings from clinical on treating aortic stenosis with statins alone or in combination with ezetimibe.
Review data from recent trials on lipid-lowering agents, and evaluate this data within current lipid-lowering strategies to develop an evidence-based strategy for reducing CV risk in patients with hypercholesterolemia. Join Drs Davidson, Jones, and Radar.
Drs Eckel, Libby, Musselman, Nesto and Nissen review evidence concerning the role of the endocannabinoid system (ECS) in cardiometabolic risk and its management. They also analyze emerging therapies for cardiometabolic risk and obesity, including compounds directed at the ECS.
Which is the most important CV risk factor in controlling the progression of CVD? Click to take the survey and compare answers. The results will help us create future CME programming. This activity is part of an independent educational grant from Abbott.
Join Drs Steven Nissen, Eva Lonn, Subodh Verma, and James Stone as they discuss how imaging can evaluate the impact of treatment of atherosclerotic cardiovascular disease and provide a valuable surrogate end point for clinical trials.
Learn about Dyslipidemia clinical condition. This new resource center provides key articles, slide kits and support material to physicians and healthcare providers of patients with dyslipidemia, plus information and data you may not easily find elsewhere! Learn more about Dyslipidemia. Supported by an independent educational grant from Abbott.
This Education center is a virtual venue for in-depth information, tools, and support material for physicians and healthcare providers involved in the care of patients presenting with any risk factor related to metabolic syndrome.
Whats new on statins in heart failure? Drs Nissen, Howlett, Roberts and Welsh discuss interesting late breaking results from the CORONA study on rosuvastatin in heart failure and put them in context with a prior subgroup analysis from TNT.
